EP2342569A4 - Screeningverfahren zur identifizierung von risikopatienten für unerwünschte hepatologische ereignisse - Google Patents

Screeningverfahren zur identifizierung von risikopatienten für unerwünschte hepatologische ereignisse

Info

Publication number
EP2342569A4
EP2342569A4 EP09810686A EP09810686A EP2342569A4 EP 2342569 A4 EP2342569 A4 EP 2342569A4 EP 09810686 A EP09810686 A EP 09810686A EP 09810686 A EP09810686 A EP 09810686A EP 2342569 A4 EP2342569 A4 EP 2342569A4
Authority
EP
European Patent Office
Prior art keywords
hepatologic
adverse
events
risk
screening method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09810686A
Other languages
English (en)
French (fr)
Other versions
EP2342569A2 (de
Inventor
Russell Medford
Kenneth M Borow
Hilda Maibach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salutria Pharmaceuticals LLC
Original Assignee
Salutria Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salutria Pharmaceuticals LLC filed Critical Salutria Pharmaceuticals LLC
Publication of EP2342569A2 publication Critical patent/EP2342569A2/de
Publication of EP2342569A4 publication Critical patent/EP2342569A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09810686A 2008-08-28 2009-08-28 Screeningverfahren zur identifizierung von risikopatienten für unerwünschte hepatologische ereignisse Withdrawn EP2342569A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9268608P 2008-08-28 2008-08-28
PCT/US2009/055430 WO2010025410A2 (en) 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events

Publications (2)

Publication Number Publication Date
EP2342569A2 EP2342569A2 (de) 2011-07-13
EP2342569A4 true EP2342569A4 (de) 2012-07-04

Family

ID=41722327

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09810686A Withdrawn EP2342569A4 (de) 2008-08-28 2009-08-28 Screeningverfahren zur identifizierung von risikopatienten für unerwünschte hepatologische ereignisse

Country Status (5)

Country Link
EP (1) EP2342569A4 (de)
JP (1) JP2012501454A (de)
CN (1) CN102257389A (de)
CA (1) CA2735582A1 (de)
WO (1) WO2010025410A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281544A1 (en) * 2010-12-30 2013-10-24 Muhammed Majeed Hepatoprotectant activity of garcinol
WO2012122024A2 (en) * 2011-03-04 2012-09-13 Russell Medford Screening method for identifying patients at risk of drug induced liver injury
CN103376323A (zh) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 载脂蛋白c-iii作为肥胖型糖尿病标志物的应用
CN103063848B (zh) * 2012-12-26 2015-06-03 潍坊三维生物工程集团有限公司 一种用免疫比浊法测定载脂蛋白c2的试剂盒
EP3555632B1 (de) * 2016-12-14 2021-03-10 Roche Diagnostics GmbH Bestimmung von bilirubin in einer probe
EP3373012A1 (de) * 2017-03-07 2018-09-12 Biopredictive Verfahren zur diagnose von arzneimittelinduzierter leberverletzung
CN110780071A (zh) * 2019-11-11 2020-02-11 彭涛 一种乙肝相关肝细胞癌的预后检测试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003501A1 (en) * 1999-03-16 2003-01-02 Judith Fitzpatrick Method and device for detection of apo a, apo b and the ratio thereof in saliva
FR2870349A1 (fr) * 2004-05-14 2005-11-18 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepatique chez un sujet et/ou pour suivre l'efficacite d'un traitement d'une telle pathologie
US20060172286A1 (en) * 2005-02-03 2006-08-03 Thierry Poynard Diagnosis method of alcholic or non-alcoholic steato-hepatitis using biochemical markers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500375A (en) 1993-04-13 1996-03-19 Serex, Inc. Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
JP2004123716A (ja) * 2002-08-06 2004-04-22 Mitsubishi Pharma Corp 化学物質に起因する肝障害の予防及び／又は治療のための医薬
AU2003296085A1 (en) * 2002-12-24 2004-07-22 Nitto Boseki Co., Ltd. Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
US8614064B2 (en) * 2003-05-23 2013-12-24 The Johns Hopkins University Methods of diagnosing atherosclerosis by measuring ApoCI
US7860656B2 (en) * 2005-02-03 2010-12-28 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of hepatic steatosis using biochemical markers
EP1726962A1 (de) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E-plasmaspiegel zur Überwachung und Reduktion des Risikos der kardiovaskulairen Erkrankungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003501A1 (en) * 1999-03-16 2003-01-02 Judith Fitzpatrick Method and device for detection of apo a, apo b and the ratio thereof in saliva
FR2870349A1 (fr) * 2004-05-14 2005-11-18 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepatique chez un sujet et/ou pour suivre l'efficacite d'un traitement d'une telle pathologie
US20060172286A1 (en) * 2005-02-03 2006-08-03 Thierry Poynard Diagnosis method of alcholic or non-alcoholic steato-hepatitis using biochemical markers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010025410A2 *

Also Published As

Publication number Publication date
JP2012501454A (ja) 2012-01-19
EP2342569A2 (de) 2011-07-13
WO2010025410A2 (en) 2010-03-04
WO2010025410A3 (en) 2010-07-01
CA2735582A1 (en) 2010-03-04
CN102257389A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
IL239277A0 (en) A method for identifying risk factors for diseases
HK1206419A1 (en) Predicting risk of major adverse cardiac events
HK1136954A1 (en) Method for manufacture of an implant device
GB0810051D0 (en) Method of diagnosis
EP2132570A4 (de) Screening-verfahren
EP2342569A4 (de) Screeningverfahren zur identifizierung von risikopatienten für unerwünschte hepatologische ereignisse
EP2029771A4 (de) Verfahren zur diagnose von myopathie
EP2455751A4 (de) Verfahren zur quantifizierung von proteinen
PL2002702T3 (pl) Sposób wstępnego kiełkowania materiału siewnego
EP2136211A4 (de) Bestimmungsverfahren für eine allergische erkrankung
EP2226632A4 (de) Screening-verfahren für zellschutzmittel
EP2232270A4 (de) Verfahren zur beurteilung der gefahr eines herzversagens
GB2474319B (en) Method and system for analysing tissue from images
TWI365420B (en) Method for defect diagnosis and management
EP2287604A4 (de) Verfahren zur untersuchung von morbus alzheimer
EP2126564A4 (de) Diagnoseverfahren
EP2243830A4 (de) Screening-verfahren
EP2438194A4 (de) Verfahren zum abtasten und identifizieren von verbindungen
GB0912992D0 (en) Method of screening for pathogens
ZA201008471B (en) Biomarker for selecting patients and related methods
EP2218492A4 (de) Verfahren zum entfernen von cio3f
EP2419512A4 (de) Verfahren zum screening nach insulinausscheidungspotenzierenden mitteln
TWI350162B (en) Method of multiple-subject image analysis using brain atlas
IL190526A0 (en) Method for identifying patients
HU0800345D0 (en) Method for monitoring bone neogenesis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110316

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20120525BHEP

Ipc: G01N 33/15 20060101ALI20120525BHEP

Ipc: G01N 33/68 20060101AFI20120525BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111123

R18D Application deemed to be withdrawn (corrected)

Effective date: 20130103